Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 473

1.

Therapeutic results of proton beam therapy with concurrent chemotherapy for cT1 esophageal cancer and salvage endoscopic therapy for local recurrence.

Sato D, Motegi A, Kadota T, Kojima T, Bando H, Shinmura K, Hori K, Yoda Y, Oono Y, Zenda S, Ikematsu H, Akimoto T, Yano T.

Esophagus. 2020 Jan 21. doi: 10.1007/s10388-020-00715-y. [Epub ahead of print]

PMID:
31965362
2.

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.

Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M.

Breast Cancer Res Treat. 2020 Jan 17. doi: 10.1007/s10549-020-05524-6. [Epub ahead of print]

PMID:
31953696
3.

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.

Kotani D, Kuboki Y, Horasawa S, Kaneko A, Nakamura Y, Kawazoe A, Bando H, Taniguchi H, Shitara K, Kojima T, Tsuji A, Yoshino T.

BMC Cancer. 2019 Dec 27;19(1):1253. doi: 10.1186/s12885-019-6475-6.

4.

Congenital pituitary hypoplasia model demonstrates hypothalamic OTX2 regulation of pituitary progenitor cells.

Matsumoto R, Suga H, Aoi T, Bando H, Fukuoka H, Iguchi G, Narumi S, Hasegawa T, Muguruma K, Ogawa W, Takahashi Y.

J Clin Invest. 2019 Dec 17. pii: 127378. doi: 10.1172/JCI127378. [Epub ahead of print]

5.

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.

Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Shinozaki E, Nakajima TE, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Takahashi K, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Ohtsu A, Yoshino T.

ESMO Open. 2019 Nov 13;4(6):e000590. doi: 10.1136/esmoopen-2019-000590. eCollection 2019.

6.

Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis.

Mitani S, Kadowaki S, Oze I, Masuishi T, Narita Y, Bando H, Oonishi S, Hirayama Y, Tanaka T, Tajika M, Koide Y, Kodaira T, Abe T, Muro K.

Cancer Med. 2020 Jan;9(1):394-400. doi: 10.1002/cam4.2688. Epub 2019 Nov 15.

7.

Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider.

Sato Y, Bando H, Di Piazza M, Gowing G, Herberts C, Jackman S, Leoni G, Libertini S, MacLachlan T, McBlane JW, Pereira Mouriès L, Sharpe M, Shingleton W, Surmacz-Cordle B, Yamamoto K, van der Laan JW.

Cytotherapy. 2019 Nov;21(11):1095-1111. doi: 10.1016/j.jcyt.2019.10.001. Epub 2019 Nov 9. Review.

8.

Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study.

Demachi K, Bando H, Nomura H, Shitara K, Yoshino T, Yamaguchi M, Kawasaki T.

Jpn J Clin Oncol. 2019 Nov 6. pii: hyz157. doi: 10.1093/jjco/hyz157. [Epub ahead of print]

PMID:
31693138
9.

Changes in Radixin Expression and Interaction with Efflux Transporters in the Liver of Adjuvant-Induced Arthritic Rats.

Kawase A, Nakasaka M, Bando H, Yasuda S, Shimada H, Iwaki M.

Inflammation. 2019 Oct 25. doi: 10.1007/s10753-019-01097-9. [Epub ahead of print]

PMID:
31654296
10.

The recurrence of colonic volvulus due to nonrotation after intestinal resection in adulthood: a case report.

Sakimura Y, Kitamura H, Inaki N, Bando H.

Surg Case Rep. 2019 Oct 21;5(1):147. doi: 10.1186/s40792-019-0710-x.

11.

Pathogenesis of Anti-PIT-1 Antibody Syndrome: PIT-1 Presentation by HLA Class I on Anterior Pituitary Cells.

Kanie K, Bando H, Iguchi G, Muguruma K, Matsumoto R, Hidaka-Takeno R, Okimura Y, Yamamoto M, Fujita Y, Fukuoka H, Yoshida K, Suda K, Nishizawa H, Ogawa W, Takahashi Y.

J Endocr Soc. 2019 Aug 26;3(11):1969-1978. doi: 10.1210/js.2019-00243. eCollection 2019 Nov 1.

12.

Function of leukaemia inhibitory factor in spermatogenesis of a teleost fish, the medaka Oryzias latipes.

Satoh R, Bando H, Sakai N, Kotani T, Yamashita M.

Zygote. 2019 Dec;27(6):423-431. doi: 10.1017/S0967199419000558. Epub 2019 Oct 16.

PMID:
31617472
13.

Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing.

Fujii S, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shinozaki E, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.

Biomed Rep. 2019 Oct;11(4):171-180. doi: 10.3892/br.2019.1235. Epub 2019 Aug 21.

14.

Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.

Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, Taniguchi H, Zhao H, Thant CN, de Stanchina E, Rosen N, Corcoran RB, Yoshino T, Yao Z, Ebi H.

Clin Cancer Res. 2019 Dec 1;25(23):7089-7097. doi: 10.1158/1078-0432.CCR-19-2004. Epub 2019 Sep 12.

PMID:
31515458
15.

Autoimmune pituitary disease: New concepts with clinical implications.

Yamamoto M, Iguchi G, Bando H, Kanie K, Hidaka-Takeno R, Fukuoka H, Takahashi Y.

Endocr Rev. 2019 Sep 12. pii: bnz003. doi: 10.1210/endrev/bnz003. [Epub ahead of print]

PMID:
31513261
16.

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.

Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Takeuchi S, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Mizushima T, Saji S, Maehara Y, Ohtsu A, Mori M.

JAMA Oncol. 2019 Sep 12. doi: 10.1001/jamaoncol.2019.2572. [Epub ahead of print]

PMID:
31513248
17.

Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial.

Shimizu Y, Yoshikawa T, Kojima T, Shoda K, Nosaka K, Mizuno S, Wada S, Fujimoto Y, Sasada T, Kohashi K, Bando H, Endo I, Nakatsura T.

Cancer Sci. 2019 Oct;110(10):3049-3060. doi: 10.1111/cas.14165. Epub 2019 Sep 19.

18.

Four New Triterpenoids from the Bark of Euonymus alatus forma ciliato-dentatus.

Yamashita H, Matsuzaki M, Kurokawa Y, Nakane T, Goto M, Lee KH, Shibata T, Bando H, Wada K.

Phytochem Lett. 2019 Jun;31:140-146. doi: 10.1016/j.phytol.2019.03.015. Epub 2019 Apr 6.

PMID:
31379978
19.

High expression of soluble CD155 in estrogen receptor-negative breast cancer.

Iguchi-Manaka A, Okumura G, Ichioka E, Kiyomatsu H, Ikeda T, Bando H, Shibuya A, Shibuya K.

Breast Cancer. 2020 Jan;27(1):92-99. doi: 10.1007/s12282-019-00999-8. Epub 2019 Aug 1.

20.

Aural stimulation with capsaicin prevented pneumonia in dementia patients.

Jinnouchi O, Ohnishi H, Kondo E, Kawata I, Bando H, Okamoto H, Azuma T, Sato G, Kitamura Y, Abe K, Takeda N.

Auris Nasus Larynx. 2019 Jul 4. pii: S0385-8146(19)30280-9. doi: 10.1016/j.anl.2019.06.008. [Epub ahead of print]

PMID:
31280931
21.

Human GBP1 is a microbe-specific gatekeeper of macrophage apoptosis and pyroptosis.

Fisch D, Bando H, Clough B, Hornung V, Yamamoto M, Shenoy AR, Frickel EM.

EMBO J. 2019 Jul 1;38(13):e100926. doi: 10.15252/embj.2018100926. Epub 2019 Jun 3.

22.

Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1.

Hozumi K, Fukuoka H, Odake Y, Takeuchi T, Uehara T, Sato T, Inoshita N, Yoshida K, Matsumoto R, Bando H, Hirota Y, Iguchi G, Taniguchi M, Otsuki N, Nishigori C, Kosaki K, Hasegawa T, Ogawa W, Takahashi Y.

Endocr J. 2019 Oct 28;66(10):853-857. doi: 10.1507/endocrj.EJ19-0035. Epub 2019 Jun 12.

23.

CXCR4 regulates Plasmodium development in mouse and human hepatocytes.

Bando H, Pradipta A, Iwanaga S, Okamoto T, Okuzaki D, Tanaka S, Vega-Rodríguez J, Lee Y, Ma JS, Sakaguchi N, Soga A, Fukumoto S, Sasai M, Matsuura Y, Yuda M, Jacobs-Lorena M, Yamamoto M.

J Exp Med. 2019 Aug 5;216(8):1733-1748. doi: 10.1084/jem.20182227. Epub 2019 Jun 12.

PMID:
31189656
24.

Toxoplasma Effector GRA15-Dependent Suppression of IFN-γ-Induced Antiparasitic Response in Human Neurons.

Bando H, Lee Y, Sakaguchi N, Pradipta A, Sakamoto R, Tanaka S, Ma JS, Sasai M, Yamamoto M.

Front Cell Infect Microbiol. 2019 May 1;9:140. doi: 10.3389/fcimb.2019.00140. eCollection 2019.

25.

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer.

Honda K, Gyawali B, Ando M, Kumanishi R, Kato K, Sugiyama K, Mitani S, Masuishi T, Narita Y, Bando H, Taniguchi H, Kadowaki S, Ura T, Muro K.

J Glob Oncol. 2019 May;5:1-8. doi: 10.1200/JGO.19.00003.

26.

Influence of Surgical Procedures and Instruments on the Incidence of Suprachoroidal Hemorrhage during 25-gauge Pars Plana Vitrectomy.

Iwama Y, Nakashima H, Emi K, Bando H, Ikeda T.

Ophthalmol Retina. 2018 Sep;2(9):888-894. doi: 10.1016/j.oret.2018.01.009. Epub 2018 Mar 3.

PMID:
31047220
27.

A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.

Bando H, Kagawa Y, Kato T, Akagi K, Denda T, Nishina T, Komatsu Y, Oki E, Kudo T, Kumamoto H, Yamanaka T, Yoshino T.

Br J Cancer. 2019 May;120(10):982-986. doi: 10.1038/s41416-019-0457-y. Epub 2019 Apr 24.

PMID:
31015557
28.

Efficiency of fluorescent cholangiography during laparoscopic cholecystectomy for subvesical bile ducts: A case report.

Kitamura H, Tsuji T, Yamamoto D, Takahashi T, Kadoya S, Kurokawa M, Bando H.

Int J Surg Case Rep. 2019;57:194-196. doi: 10.1016/j.ijscr.2019.03.042. Epub 2019 Mar 30.

29.

Differential isoform expression of SERCA and myosin heavy chain in hypopharyngeal muscles.

Elrabie Ahmed M, Bando H, Fuse S, Mostafa Abdelfattah H, Elrabie Ahmed M, Abdel-Kader Ahmed M, Tsujikawa T, Hisa Y.

Acta Otorhinolaryngol Ital. 2019 Aug;39(4):220-229. doi: 10.14639/0392-100X-2185. Epub 2019 Mar 25.

30.

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.

Harada K, Okamoto W, Mimaki S, Kawamoto Y, Bando H, Yamashita R, Yuki S, Yoshino T, Komatsu Y, Ohtsu A, Sakamoto N, Tsuchihara K.

BMC Cancer. 2019 Mar 21;19(1):255. doi: 10.1186/s12885-019-5479-6.

31.

The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial.

Sagawa N, Ohno S, Hiratsuka T, Kondo N, Iwata H, Bando H, Ohyama T, Ishida M, Kono Y, Nakajima K, Empuku S, Nishikawa S, Irie Y, Inomata M, Kitano S.

Breast Cancer Res Treat. 2019 Aug;176(3):625-630. doi: 10.1007/s10549-019-05164-5. Epub 2019 Feb 26.

PMID:
30806921
32.

Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial.

Muro K, Itabashi M, Hashida H, Masuishi T, Bando H, Denda T, Yamanaka T, Ohashi Y, Sugihara K.

Jpn J Clin Oncol. 2019 Apr 1;49(4):339-346. doi: 10.1093/jjco/hyy189.

33.

Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.

Ishiguro H, Ohno S, Yamamoto Y, Takao S, Sato N, Fujisawa T, Kadoya T, Kuroi K, Bando H, Teramura Y, Iwata H, Tanaka S, Toi M.

Breast Cancer. 2019 Sep;26(5):535-543. doi: 10.1007/s12282-019-00952-9. Epub 2019 Feb 7.

34.

Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.

Esaki T, Hirai F, Makiyama A, Seto T, Bando H, Naito Y, Yoh K, Ishihara K, Kakizume T, Natsume K, Myers A, Doi T.

Cancer Sci. 2019 Apr;110(4):1340-1351. doi: 10.1111/cas.13956. Epub 2019 Feb 20.

35.

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.

Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Tsuji A, Shitara K.

J Immunother Cancer. 2019 Jan 31;7(1):24. doi: 10.1186/s40425-019-0514-3.

36.

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.

Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K.

Gastric Cancer. 2019 Jul;22(4):793-802. doi: 10.1007/s10120-018-00922-8. Epub 2019 Jan 9.

PMID:
30627987
37.

IgG4-related hypophysitis in patients with autoimmune pancreatitis.

Kanie K, Bando H, Iguchi G, Shiomi H, Masuda A, Fukuoka H, Nishizawa H, Fujita Y, Sakai A, Kobayashi T, Shiomi Y, Yoshida K, Matsumoto R, Suda K, Kodama Y, Ogawa W, Takahashi Y.

Pituitary. 2019 Feb;22(1):54-61. doi: 10.1007/s11102-018-00930-y.

PMID:
30607745
38.

Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.

Nakamura Y, Yamanaka T, Chin K, Cho H, Katai H, Terashima M, Misawa K, Hirao M, Yoshida K, Oki E, Sasako M, Emi Y, Bando H, Kawashima Y, Fukunaga T, Gotoh M, Ishibashi T, Shitara K.

Ann Surg Oncol. 2019 Feb;26(2):465-472. doi: 10.1245/s10434-018-7063-8. Epub 2018 Nov 19.

PMID:
30456678
39.

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma.

Mishima S, Kawazoe A, Matsumoto H, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Nonte EM, Chintharlapalli S, Nasir A, Kuwata T, Shitara K.

ESMO Open. 2018 Nov 1;3(7):e000443. doi: 10.1136/esmoopen-2018-000443. eCollection 2018.

40.

Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab.

Watanabe R, Nakano E, Kawazoe A, Kuboki Y, Bando H, Shitara K, Takahashi A, Tsutsumida A, Nishizawa A, Yamazaki N.

J Dermatol. 2019 May;46(5):e178-e180. doi: 10.1111/1346-8138.14693. Epub 2018 Oct 31. No abstract available.

PMID:
30379358
41.

Inducible Nitric Oxide Synthase Is a Key Host Factor for Toxoplasma GRA15-Dependent Disruption of the Gamma Interferon-Induced Antiparasitic Human Response.

Bando H, Lee Y, Sakaguchi N, Pradipta A, Ma JS, Tanaka S, Cai Y, Liu J, Shen J, Nishikawa Y, Sasai M, Yamamoto M.

mBio. 2018 Oct 9;9(5). pii: e01738-18. doi: 10.1128/mBio.01738-18.

42.

Toxoplasma Effector TgIST Targets Host IDO1 to Antagonize the IFN-γ-Induced Anti-parasitic Response in Human Cells.

Bando H, Sakaguchi N, Lee Y, Pradipta A, Ma JS, Tanaka S, Lai DH, Liu J, Lun ZR, Nishikawa Y, Sasai M, Yamamoto M.

Front Immunol. 2018 Sep 19;9:2073. doi: 10.3389/fimmu.2018.02073. eCollection 2018.

43.

Insulin secretion of mixed insulinoma aggregates-gelatin hydrogel microspheres after subcutaneous transplantation.

Inoo K, Bando H, Tabata Y.

Regen Ther. 2018 Feb 2;8:38-45. doi: 10.1016/j.reth.2018.01.003. eCollection 2018 Jun.

44.

Enhanced survival and insulin secretion of insulinoma cell aggregates by incorporating gelatin hydrogel microspheres.

Inoo K, Bando H, Tabata Y.

Regen Ther. 2018 Feb 4;8:29-37. doi: 10.1016/j.reth.2017.12.002. eCollection 2018 Jun.

45.

Development and pharmacist-mediated use of tools for monitoring atypical antipsychotic-induced side effects related to blood glucose levels.

Ishida S, Takechi K, Bando H, Imanishi M, Zamami Y, Chuma M, Yanagawa H, Kirino Y, Nakamura T, Teraoka K, Ishizawa K.

Pharmacoepidemiol Drug Saf. 2018 Dec;27(12):1379-1384. doi: 10.1002/pds.4656. Epub 2018 Sep 17.

PMID:
30221424
46.

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).

Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association.

Cancer Sci. 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730.

47.

Utility of the quasi-monomorphic variation range in unresectable metastatic colorectal cancer patients.

Bando H, Okamoto W, Fukui T, Yamanaka T, Akagi K, Yoshino T.

Cancer Sci. 2018 Nov;109(11):3411-3415. doi: 10.1111/cas.13774. Epub 2018 Oct 2.

48.

Preoperative diagnosis of a giant cell tumor of soft tissue arising from the breast by ultrasound-guided core needle biopsy.

Sawa A, Ikeda T, Ichioka E, Tsushima Y, Iguchi-Manaka A, Bando H, Kondo Y, Hara H.

J Med Ultrason (2001). 2019 Apr;46(2):257-261. doi: 10.1007/s10396-018-0891-0. Epub 2018 Jul 30.

PMID:
30062496
49.

The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies.

Sawada K, Kotani D, Bando H.

Front Oncol. 2018 Jul 16;8:263. doi: 10.3389/fonc.2018.00263. eCollection 2018. Review.

50.

Isolated adrenocorticotropic hormone deficiency as a form of paraneoplastic syndrome.

Bando H, Iguchi G, Kanie K, Nishizawa H, Matsumoto R, Fujita Y, Odake Y, Yoshida K, Suda K, Fukuoka H, Tanaka K, Ogawa W, Takahashi Y.

Pituitary. 2018 Oct;21(5):480-489. doi: 10.1007/s11102-018-0901-7.

PMID:
30008158

Supplemental Content

Support Center